Karl serves as Chief Clinical Officer at T-CURX with over 15 years of experience in Clinical Development. Most recently, he was the CMO at Tolremo Therapeutics AG and supported the preclinical to clinical transition activities. Prior to that he was Vice President Clinical Development at Merck KGaA where he was responsible for the early oncology clinical development and the DDR portfolio. He was successfully supporting as clinical lead the approval process of the C-MET inhibitor Tepotinib in lung cancer patients. Before this Karl was at Sandoz AG where he developed successfully the infliximab biosimilar Ixifi in collaboration with Pfizer. Earlier, Karl was also clinical lead at Novartis AG leading the early clinical development of the alpha specific PI3K-inhibitor Piqray in breast cancer patients and the BRAF/MEK inhibitor combination Encorafenib/Binimetinib in melanoma patients and he was Medical Director at Merck KGaA on the FLEX trial (Erbitux plus chemotherapy) in lung cancer patients.

Karl is a MD and graduated from the University Hospital Bonn, Germany, where he afterwards worked as resident in the surgical/urological center with focus on surgical oncology. Karl received his habilitation at the University of Regensburg and was a team lead at the Institute of Bioengineering in Singapore. During this time he authored more than 20 publications in the field of tissue engineering, bioprinting and cell therapy. He holds various patents in the tissue engineering field for tubular structures for regenerative medicine. Karl is member of the medical faculty at the University Heidelberg and he obtained an MHBA from the economic faculty of the University of Erlangen, Germany.